BIAS
RXRX icon

Beacon Investment Advisory Services’s Recursion Pharmaceuticals RXRX Stock Holding History

Beacon Investment Advisory Services’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.34K Hold
2,000
– – ﹤0.01% 650
2026
Q1 		$6.14K Buy
+2,000
New +$7.73K ﹤0.01% 679

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Beacon Investment Advisory Services's RXRX Position: Q2 2026 in Review

Beacon Investment Advisory Services held its Recursion Pharmaceuticals (RXRX) position steady in Q2 2026 at 2,000 shares worth $7.34K. The position accounts for ﹤0.01% of the portfolio, ranked #650.

Beacon Investment Advisory Services first reported a position in RXRX in Q1 2026 and has held it in 2 quarters since. 342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Beacon Investment Advisory Services held 2,000 shares of Recursion Pharmaceuticals worth $7.34K as of Q2 2026.
  • Beacon Investment Advisory Services left its Recursion Pharmaceuticals share count unchanged in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Beacon Investment Advisory Services's portfolio in Q2 2026, its #650 holding.
  • Beacon Investment Advisory Services first reported a position in Recursion Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Beacon Investment Advisory Services's 13F filing for Q2 2026, filed 8 Jul 2026.